Genetic Technologies Ltd.
GENE
GENE was delisted on the 16th of October, 2024.
12 hedge funds and large institutions have $212K invested in Genetic Technologies Ltd. in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
800% more call options, than puts
Call options by funds: $9K | Put options by funds: $1K
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
50% more funds holding
Funds holding: 8 → 12 (+4)
4% more capital invested
Capital invested by funds: $205K → $212K (+$7.34K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$60.8K |
| 2 |
VF
Virtu Financial
New York
|
+$18.6K |
| 3 |
SA
Scarborough Advisors
Annapolis,
Maryland
|
+$12.5K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$12K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$70K |
| 2 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$56.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4.38K |
| 4 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$116 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $118K | +$60.8K | +10,380 | +103% |
|
|
OMC
2
Old Mission Capital
Chicago,
Illinois
| $25.1K | -$56.9K | -9,726 | -69% |
|
|
VF
3
Virtu Financial
New York
| $19K | +$18.6K | +3,173 | New |
|
|
CA
4
Cetera Advisors
Denver,
Colorado
| $16.2K | – | – | – |
|
|
SA
5
Scarborough Advisors
Annapolis,
Maryland
| $12.3K | +$12.5K | +2,128 | New |
|
|
TSS
6
Two Sigma Securities
New York
| $11.9K | +$12K | +2,055 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| $4.24K | -$4.38K | -749 | -51% |
|
|
FDCDDQ
8
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $2.32K | – | – | – |
|
|
9
Citadel Advisors
Miami,
Florida
| $1.41K | +$1.42K | +242 | New |
|
10
Wells Fargo
San Francisco,
California
| $1.16K | – | – | – |
|
|
11
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$70K | -15,376 | Closed |
|
|
NA
12
NewEdge Advisors
New Orleans,
Louisiana
| – | -$116 | -25 | Closed |
|
|
TRCT
13
Tower Research Capital (TRC)
New York
| – | +$6 | +1 | New |
|
14
Simplex Trading
Chicago,
Illinois
| – | +$246 | +42 | New |
|
GENE Hedge Fund Activity: Q1 2023 in Review
12 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Genetic Technologies Ltd. (GENE) for Q1 2023, worth a combined $212K — up 3.6% from $205K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new GENE positions and 2 closed out — a net gain of 4 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $60.8K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $70K sold.
- 12 institutional investors held Genetic Technologies Ltd. (GENE) as of Q1 2023, up from 8 in Q4 2022.
- Funds reported $212K of Genetic Technologies Ltd. stock for Q1 2023, up 3.6% quarter-over-quarter.
- 6 funds opened new Genetic Technologies Ltd. positions in Q1 2023 and 2 closed out, a net change of +4 holders.
- The largest Genetic Technologies Ltd. buyer in Q1 2023 was Morgan Stanley, an estimated $60.8K added.
- The largest Genetic Technologies Ltd. seller in Q1 2023 was Susquehanna International Group, an estimated $70K sold.
Based on aggregated 13F filings for Q1 2023.